NCT03847649 - A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 9, 2020

Primary Completion Date

April 30, 2030

Study Completion Date

April 30, 2031

Conditions

Cancer

Interventions

DRUG

Durvalumab

1500 mg IV, 60 min, Day 1 every 4 weeks

DRUG

Prednisone

0.5mg/kg; PO, Daily cycles 1 \& 2

DRUG

Prednisone

10mg, PO, Daily cycles 1 \& 2

DRUG

Tremelimumab

Patients previously enrolled on a completed CCTG trial to continue treatment with durvalumab (+/- tremelimumab)

Trial Locations (12)

T6G 1Z2

RECRUITING

Cross Cancer Institute, Edmonton

V1Y 5L3

RECRUITING

BCCA - Kelowna, Kelowna

V5Z 4E6

RECRUITING

BCCA - Vancouver, Vancouver

E2L 4L2

RECRUITING

Regional Health Authority B, Zone 2, Saint John

L8V 5C2

RECRUITING

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

N2G 1G3

RECRUITING

Waterloo Regional Health Network (WRHN), Kitchener

K1H 8L6

RECRUITING

Ottawa Hospital Research Institute, Ottawa

M5G 2M9

RECRUITING

University Health Network, Toronto

N8W 2X3

RECRUITING

Windsor Regional Cancer Centre, Windsor

H2X 3E4

RECRUITING

CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal

G1J 1Z4

RECRUITING

CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Québec

S7N 4H4

RECRUITING

Saskatoon Cancer Centre, Saskatoon